The FDA approved a new injected version of the cancer immunotherapy drug Keytruda. With injections, patients need only an hour total for treatment, while Keytruda infusion may require two hours.

Both Opdivo and Keytruda come as liquid solutions. The two drugs are given as an intravenous (IV) infusion, which is an injection into your vein given over a period of time. Infusions for both Opdivo ...

The FDA approved Merck's Keytruda Qlex, a new under-the-skin version of the cancer drug that can be injected in just 1-2 minutes, offering faster and more convenient treatment than traditional IV ...

Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety ...

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Merck & Co., Inc. is placed fourth among them. Merck & Co., Inc. (NYSE:MRK), a global ...

KEYNOTE-689 marks the first positive trial in more than two decades for patients with resected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) Results to be presented at American ...

Canada's health regulator has approved Merck's new under-the-skin version of its cancer drug Keytruda, offering an alternative to the current intravenous infusion. Health Canada has approved Keytruda ...

– The First Pivotal Phase 3 Trial to Demonstrate Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care Keytruda plus Chemotherapy in 1L mTNBC – – Trodelvy ...

FDA approved pembrolizumab plus paclitaxel ± bevacizumab for PD-L1 CPS ≥1 platinum-resistant ovarian/fallopian tube/primary peritoneal carcinoma after 1–2 prior systemic therapies. KEYNOTE-B96 ...